NZ599839A - Synergistic antiviral composition and use thereof - Google Patents

Synergistic antiviral composition and use thereof

Info

Publication number
NZ599839A
NZ599839A NZ599839A NZ59983910A NZ599839A NZ 599839 A NZ599839 A NZ 599839A NZ 599839 A NZ599839 A NZ 599839A NZ 59983910 A NZ59983910 A NZ 59983910A NZ 599839 A NZ599839 A NZ 599839A
Authority
NZ
New Zealand
Prior art keywords
antiviral composition
synergistic antiviral
neuraminidase inhibitor
laninamivir
peramivir
Prior art date
Application number
NZ599839A
Other languages
English (en)
Inventor
Andreas Grassauer
Eva Prieschl-Grassauer
Christiane Meier
Marielle Konig-Schuster
Original Assignee
Marinomed Biotechnologie Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44063696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ599839(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Marinomed Biotechnologie Gmbh filed Critical Marinomed Biotechnologie Gmbh
Publication of NZ599839A publication Critical patent/NZ599839A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731Carrageenans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
NZ599839A 2009-12-22 2010-12-17 Synergistic antiviral composition and use thereof NZ599839A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28214809P 2009-12-22 2009-12-22
PCT/EP2010/007726 WO2011076367A2 (en) 2009-12-22 2010-12-17 Synergistic antiviral composition and use thereof

Publications (1)

Publication Number Publication Date
NZ599839A true NZ599839A (en) 2014-02-28

Family

ID=44063696

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ599839A NZ599839A (en) 2009-12-22 2010-12-17 Synergistic antiviral composition and use thereof

Country Status (21)

Country Link
US (1) US10022449B2 (enExample)
EP (1) EP2515889B1 (enExample)
JP (1) JP5902628B2 (enExample)
KR (1) KR101862415B1 (enExample)
CN (1) CN102652017A (enExample)
AU (1) AU2010335594B2 (enExample)
BR (1) BR112012015202B1 (enExample)
CA (1) CA2779532C (enExample)
CL (1) CL2012001695A1 (enExample)
DK (1) DK2515889T3 (enExample)
EA (1) EA022840B1 (enExample)
ES (1) ES2531367T3 (enExample)
IL (1) IL219552A (enExample)
MX (1) MX2012007166A (enExample)
NZ (1) NZ599839A (enExample)
PL (1) PL2515889T3 (enExample)
PT (1) PT2515889E (enExample)
SG (1) SG181421A1 (enExample)
SI (1) SI2515889T1 (enExample)
WO (1) WO2011076367A2 (enExample)
ZA (1) ZA201202482B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012126777A1 (en) * 2011-03-18 2012-09-27 Marinomed Biotechnologie Gmbh Inhibition of neuraminidase activity
RU2469020C1 (ru) * 2011-11-08 2012-12-10 Александр Васильевич Иващенко (3r,4r,5s)-5-амино-4-ациламино-3-(1-этил-пропокси)-циклогекс-1-ен-карбоновые кислоты, их эфиры и способ применения
RU2520836C1 (ru) * 2013-02-27 2014-06-27 Александр Васильевич Иващенко (3r,4r,5s)-4-амино-5-(2,2-дифторацетиламино)-3-(1-этилпропокси)-циклогекс-1-енкарбоновая кислота и ее эфиры, способ их получения и применения
HUE044329T2 (hu) * 2014-01-22 2019-10-28 Visufarma B V Iota-karragént tartalmazó készítmény vírusos kötõhártya-gyulladás ellen
CN117942405A (zh) * 2016-02-25 2024-04-30 应用生物实验室公司 保护空气传播的病原体和刺激物的组合物和方法
US11304989B2 (en) * 2017-10-06 2022-04-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Peptides for use in the treatment of viral infections
WO2019160261A1 (ko) * 2018-02-14 2019-08-22 (주)나노메디카 항바이러스 처리 방법, 항바이러스 필터, 및 이를 구비한 마스크
KR102316819B1 (ko) * 2018-04-20 2021-10-25 한미약품 주식회사 카라기난을 유효성분으로 포함하는 보존성이 개선된 액상 제제
GB2579600B (en) 2018-12-05 2023-07-05 Byotrol Plc Anti-viral composition
US12245754B2 (en) * 2019-07-03 2025-03-11 Aillis Inc. Pharmaceutical composition for treating influenza virus infections
WO2021184123A1 (en) * 2020-03-18 2021-09-23 Encyt Technologies, Inc. Compositions and methods for the treatment of coronavirus infection and respiratory compromise

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593314B1 (en) * 1999-10-19 2003-07-15 Abbott Laboratories Neuraminidase inhibitors
JP2001181188A (ja) * 1999-12-28 2001-07-03 Marine Biotechnol Inst Co Ltd インフルエンザウイルス感染阻害剤
DE602007005697D1 (de) 2006-12-05 2010-05-12 Marinomed Biotechnologie Gmbh Verwendung von carrageenan zur behandlung von rhinovirus-infektionen
EP1930015A1 (en) * 2006-12-05 2008-06-11 Marinomed Biotechnologie GmbH Use of carrageenan for treating rhinovirus infections
CA2673313A1 (en) * 2006-12-18 2008-12-04 Amcol International Virus-interacting layered phyllosilicates and methods of use
PL2178533T3 (pl) 2007-08-24 2013-08-30 Marinomed Biotechnologie Gmbh Kompozycja przeciwwirusowa zawierająca siarczanowany polisacharyd: jota-karagen

Also Published As

Publication number Publication date
KR101862415B1 (ko) 2018-05-29
SG181421A1 (en) 2012-07-30
PT2515889E (pt) 2015-03-20
AU2010335594A1 (en) 2012-05-24
ES2531367T3 (es) 2015-03-13
PL2515889T3 (pl) 2015-05-29
SI2515889T1 (sl) 2015-04-30
EA022840B1 (ru) 2016-03-31
CL2012001695A1 (es) 2013-03-08
US10022449B2 (en) 2018-07-17
DK2515889T3 (en) 2015-03-02
EA201290373A1 (ru) 2012-11-30
JP2013515022A (ja) 2013-05-02
IL219552A0 (en) 2012-06-28
CA2779532C (en) 2018-05-22
CN102652017A (zh) 2012-08-29
MX2012007166A (es) 2012-07-23
ZA201202482B (en) 2012-12-27
EP2515889A2 (en) 2012-10-31
JP5902628B2 (ja) 2016-04-13
IL219552A (en) 2016-11-30
BR112012015202B1 (pt) 2020-12-08
WO2011076367A2 (en) 2011-06-30
KR20120107970A (ko) 2012-10-04
BR112012015202A2 (pt) 2016-04-05
EP2515889B1 (en) 2014-12-10
WO2011076367A3 (en) 2011-09-01
US20120302522A1 (en) 2012-11-29
AU2010335594B2 (en) 2015-05-21
CA2779532A1 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
NZ599839A (en) Synergistic antiviral composition and use thereof
IN2012DN02805A (enExample)
MX341684B (es) Composicion para el uso en la prevencion y/o tratamiento de condiciones de la piel y enfermedades de la piel.
TN2011000370A1 (en) Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
MX338712B (es) Composicion farmaceutica que comprende linagliptina y opcionalmente un inhibidor de sglt2, y usos de la misma.
PH12013501842A1 (en) Pharmaceutical compositions comprising metformin and a dpp-4 inhibitor or a sglt-2 inhibitor
IL203448A (en) History of azabiphenylaminobenzoic acid for use in the treatment or prevention of a pathological condition or disease susceptible to reduction by dhodh inhibition and medicinal preparations containing them
JO3199B1 (ar) مركبات 5- فلورو-1h- بيرازولوبيريدينات مستبدلة واستخدامها
PH12013501143A1 (en) Substituted 1-benzylcycloalkylcarboxlic acids and use thereof
MY183588A (en) New salvianolic acid compound l, preparation method and use thereof
MY157860A (en) Prevention and treatment of secondary infections following viral infection
JO2581B1 (en) Aryl sulfonomides replaced
GB0625648D0 (en) Compounds
ES2429422R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH
UA107687C2 (ru) Комбинированная композиция, которая в качестве активных ингредиентов содержит l-карнитин или пропионил-l-карнитин, троксерутин, диосмин и гесперидин, для предотвращения и/или лечения хронических заболеваний вен.
MY173491A (en) Therapeutic or prophylactic agent for biliary tract diseases
MX2013002261A (es) N-fenetiltriazolonacetamidas sustituidas y su uso.
MY151590A (en) Substituted quinolones iii
JO2965B1 (en) The use of ferroxine in the treatment or prevention of malaria
UA100918C2 (ru) Мягкая лекарственная форма (мазь)
EA201490935A1 (ru) Терапевтическая комбинация мемантина и баклофена и содержащая их фармацевтическая композиция
TN2011000008A1 (en) Use of hdac inhibitors for the treatment of hodgkin's disease
UA101501C2 (ru) Средство для лечения заболеваний, вызванных патогенными микроорганизмами и воспалительными процессами, рогальских
TH149179A (th) องค์ประกอบทางเภสัชกรรม, รูปแบบเภสัชภัณฑ์, กระบวนการในการเตรียมองค์ประกอบ และรูปแบบดังกล่าว, วิธีการในการรักษา และการใช้องค์ประกอบและรูปแบบดังกล่าว

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2015 BY EUROPEAN PATENT ANNUITY SERVICE GMBH

Effective date: 20141126

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2016 BY EUROPEAN PATENT ANNUITY SERVICE GMBH

Effective date: 20151125

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2017 BY EUROPEAN PATENT ANNUITY SERVICE GMBH

Effective date: 20161124

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2018 BY EUROPEAN PATENT ANNUITY SERVICE GMBH

Effective date: 20171130

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2019 BY EUROPEAN PATENT ANNUITY SERVICE GMBH

Effective date: 20181121

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2020 BY EUROPEAN PATENT ANNUITY SERVICE GMBH

Effective date: 20191127

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2021 BY EUROPEAN PATENT ANNUITY SERVICE GMBH

Effective date: 20201204

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2022 BY EUROPEAN PATENT ANNUITY SERVICE GMBH

Effective date: 20211127

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2023 BY EUROPEAN PATENT ANNUITY SERVICE GMBH

Effective date: 20221122

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2024 BY EUROPEAN PATENT ANNUITY SERVICE GMBH

Effective date: 20231122

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2025 BY EUROPEAN PATENT ANNUITY SERVICE GMBH

Effective date: 20241129